An Open-Label, Bayesian Adaptive Phase II Clinical Study in HR+/HER2- Advanced Breast Cancer After Progression on Standard Therapy

NCT07117630 · clinicaltrials.gov ↗

PHASE2

Phase

RECRUITING

Status

20

Enrollment

OTHER

Sponsor class

Conditions

Breast Cancer

Interventions

DRUG: L-Ornithine L-Aspartate
DRUG: CDK4/6 inhibitor
DRUG: Fulvestrant

Sponsor

Fudan University